All Stories

  1. HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda

    Article • Journal of Antimicrobial Chemotherapy, November 2025, Oxford University Press (OUP)

    Willy SSENGOOBA

  2. Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)

    Article • Clinical Infectious Diseases, November 2025, Oxford University Press (OUP)

    Willy SSENGOOBA

  3. Neural network-based identification of easily-obtainable demographic and clinical characteristics to identify people with tuberculosis

    Article • October 2025, Cold Spring Harbor Laboratory Press

    Willy SSENGOOBA

  4. Performance evaluation of alternative bacteriological measures of response to MDR/RR-TB therapy during the initial 16 weeks of treatment

    Article • BMC Infectious Diseases, October 2025, Springer Science + Business Media

    Willy SSENGOOBA

  5. Association of viral exposure with tuberculosis disease progression: A systematic review

    Article • Microbial Pathogenesis, September 2025, Elsevier

    Willy SSENGOOBA

  6. Novel and optimized diagnostics for pediatric TB in endemic countries: NOD-pedFEND study protocol

    Article • BMC Pediatrics, August 2025, Springer Science + Business Media

    Willy SSENGOOBA

  7. Gaps in TB-related knowledge and practices: An assessment of health care seeking behavior among adults with HIV and caregivers of paediatric patients with presumptive TB symptoms in Manhiça district, southern Mozambique

    Article • PLOS Global Public Health, August 2025, PLOS

    Willy SSENGOOBA

  8. Performance of stool Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis among adults living with HIV: a multicentre, prospective diagnostic study

    Article • The Lancet Microbe, July 2025, Elsevier

    Willy SSENGOOBA

  9. Performance evaluation of the Molbio diagnostics Truenat MTB Ultima/COVID-19 multiplex assay for TB and COVID-19 case detection among people with symptoms suggestive of tuberculosis—a study protocol for clinical trials

    Article • Frontiers in Public Health, June 2025, Frontiers

    Willy SSENGOOBA

  10. Deciphering rifampicin resistance among tuberculosis patients who have trace results on Xpert MTB/RIF ultra assay

    Article • June 2025, Cold Spring Harbor Laboratory Press

    Willy SSENGOOBA

  11. Diagnostic accuracy of point-of-care triage tests for pulmonary tuberculosis using host blood protein biomarkers: a systematic review and meta-analysis

    Article • EClinicalMedicine, June 2025, Elsevier

    Willy SSENGOOBA

  12. Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis

    Article • The Lancet Microbe, June 2025, Elsevier

    Willy SSENGOOBA

  13. Performance evaluation of alternative bacteriological measures of response to MDR-TB therapy during the initial 16 weeks of treatment

    Article • April 2025, Springer Science + Business Media

    Willy SSENGOOBA

  14. Oral Swab Testing With Xpert MTB/RIF Ultra for the Diagnosis of Tuberculosis in Children Aged <5 Years in Uganda: An Exploratory Interim Analysis of Diagnostic Accuracy in the NOD-pedFEND Cohort

    Article • Open Forum Infectious Diseases, March 2025, Oxford University Press (OUP)

    Willy SSENGOOBA

  15. Antimycobacterial Activities of the Zanthoxylum leprieurii Metabolite Adubangoamide and Non-Natural Fagaramide Analogues

    Article • Journal of Natural Products, February 2025, American Chemical Society (ACS)

    Willy SSENGOOBA

  16. Uptake and rollout of the World Health Organization-endorsed technologies for Tuberculosis diagnosis in Africa: A systematic review of international evidence 2007-2021

    Article • February 2025, Cold Spring Harbor Laboratory Press

    Willy SSENGOOBA

  17. Non-sputum-based samples and biomarkers for detection of Mycobacterium tuberculosis: the hope to improve childhood and HIV-associated tuberculosis diagnosis

    Article • European Journal of Medical Research, October 2024, Springer Science + Business Media

    Willy SSENGOOBA

  18. Airway microbiome signature accurately discriminates Mycobacterium tuberculosis infection status

    Article • iScience, June 2024, Elsevier

    Willy SSENGOOBA

  19. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries

    Article • Nature Communications, May 2024, Springer Science + Business Media

    Willy SSENGOOBA

  20. A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosis

    Article • The Lancet Global Health, May 2024, Elsevier

    Willy SSENGOOBA

  21. Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial

    Article • Clinical Infectious Diseases, April 2024, Oxford University Press (OUP)

    Willy SSENGOOBA

  22. Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda

    Article • The Lancet Microbe, April 2024, Elsevier

    Willy SSENGOOBA

  23. Predisposing, enabling, and need factors influencing rapid uptake of the World Health Organization-endorsed TB diagnostic technologies in Africa

    Article • March 2024, Cold Spring Harbor Laboratory Press

    Willy SSENGOOBA

  24. A stool based qPCR for the diagnosis of TB in children and people living with HIV in Uganda, Eswatini and Mozambique (Stool4TB): a protocol for a multicenter diagnostic evaluation

    Article • BMC Infectious Diseases, February 2024, Springer Science + Business Media

    Willy SSENGOOBA

  25. Performance evaluation of Truenat MTB and Truenat MTB-RIF DX assays in comparison to gene XPERT MTB/RIF ultra for the diagnosis of pulmonary tuberculosis in Uganda

    Article • BMC Infectious Diseases, February 2024, Springer Science + Business Media

    Willy SSENGOOBA

  26. Effect of mixed Mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda

    Article • BMC Infectious Diseases, January 2024, Springer Science + Business Media

    Willy SSENGOOBA

  27. Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials

    Article • The Lancet Microbe, November 2023, Elsevier

    Willy SSENGOOBA

  28. Geographic distribution and predictors of diagnostic delays among possible TB patients in Uganda

    Article • Public Health Action, September 2023, International Union Against Tuberculosis and Lung Disease

    Willy SSENGOOBA

  29. Evaluation of Xpert MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda

    Article • PLOS One, August 2023, PLOS

    Willy SSENGOOBA

  30. Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV

    Article • The Pediatric Infectious Disease Journal, July 2023, Wolters Kluwer Health

    Willy SSENGOOBA

  31. Evaluation of Xpert®MTB/XDR test for susceptibility testing ofMycobacterium tuberculosisto first and second-line drugs in Uganda

    Article • April 2023, Cold Spring Harbor Laboratory Press

    Willy SSENGOOBA

  32. Two new compounds and the anti-mycobacterial activity of the constituents from Zanthoxylum leprieurii root bark

    Article • Phytochemistry Letters, April 2023, Elsevier

    Willy SSENGOOBA

  33. Lots of considerations when evaluating the FujiLAM assay

    Article • The Lancet Global Health, April 2023, Elsevier

    Willy SSENGOOBA

  34. Second-line drug resistance markers as proxy indicators of time to sputum culture conversion among second-line drug resistant tuberculosis patients tested in Uganda: A cross-sectional study

    Article • F1000Research, January 2023, Faculty of 1000, Ltd.

    Willy SSENGOOBA

  35. Cardiovascular risk factors among people with drug-resistant tuberculosis in Uganda

    Article • BMC Cardiovascular Disorders, November 2022, Springer Science + Business Media

    Willy SSENGOOBA

  36. Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment

    Article • The International Journal of Tuberculosis and Lung Disease, November 2022, International Union Against Tuberculosis and Lung Disease

    Willy SSENGOOBA

  37. Prevalence and antimicrobial resistance profiles of Neisseria gonorrhea and Chlamydia trachomatis isolated from individuals attending STD clinics in Kampala, Uganda

    Article • African Health Sciences, October 2022, African Journals Online (AJOL)

    Dr Gerald Mboowa, Willy SSENGOOBA

  38. Strategies to Reduce Mortality Among Children Living With HIV and Children Exposed to HIV but Are Uninfected, Admitted With Severe Acute Malnutrition at Mulago Hospital, Uganda (REDMOTHIV): A Mixed Methods Study

    Article • Frontiers in Pediatrics, June 2022, Frontiers

    Willy SSENGOOBA

  39. Recurrent pneumothorax in a human immunodeficiency virus-positive patient with multidrug-resistant tuberculosis: a rare case of bronchopleural fistula: a case report

    Article • Journal of Medical Case Reports, May 2022, Springer Science + Business Media

    Willy SSENGOOBA

  40. Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year’s review

    Article • BMC Infectious Diseases, April 2022, Springer Science + Business Media

    Willy SSENGOOBA

  41. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children

    Article • New England Journal of Medicine, March 2022, New England Journal of Medicine (NEJM/MMS)

    Willy SSENGOOBA

  42. High Mycobacterium tuberculosis Bacillary Loads Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of Tuberculosis

    Article • Microbiology Spectrum, February 2022, ASM Journals

    Willy SSENGOOBA

  43. Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy

    Article • Scientific Reports, December 2021, Springer Science + Business Media

    Willy SSENGOOBA

  44. Performance and cost-effectiveness of a pooled testing strategy for SARS-CoV-2 using real-time polymerase chain reaction in Uganda

    Article • International Journal of Infectious Diseases, December 2021, Elsevier

    Willy SSENGOOBA

  45. Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

    Article • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, December 2021, Elsevier

    Willy SSENGOOBA

  46. Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert® MTB/RIF

    Article • The International Journal of Tuberculosis and Lung Disease, November 2021, International Union Against Tuberculosis and Lung Disease

    Willy SSENGOOBA

  47. Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA)

    Article • Expert Review of Anti-infective Therapy, September 2021, Taylor & Francis

    Willy SSENGOOBA

  48. Antimycobacterial Activity of the Extract and Isolated Compounds From the Stem Bark of Zanthoxylum leprieurii Guill. and Perr.

    Article • Natural Product Communications, August 2021, SAGE Publications

    Willy SSENGOOBA

  49. Assessing a transmission network of Mycobacterium tuberculosis in an African city using single nucleotide polymorphism threshold analysis

    Article • MicrobiologyOpen, June 2021, Wiley

    Willy SSENGOOBA

  50. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study

    Article • BMC Infectious Diseases, June 2021, Springer Science + Business Media

    Willy SSENGOOBA

  51. Effectiveness of thermal screening in detection of COVID-19 among truck drivers at Mutukula Land Point of Entry, Uganda

    Article • PLOS One, May 2021, PLOS

    Willy SSENGOOBA

  52. Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda

    Article • Open Forum Infectious Diseases, April 2021, Oxford University Press (OUP)

    Willy SSENGOOBA

  53. The simple direct slide method is comparable to indirect Lowenstein Jensen proportion culture for detecting rifampicin resistant tuberculosis

    Article • Journal of Medical Microbiology, March 2021, Society for General Microbiology

    Willy SSENGOOBA

  54. Chest X-ray interpretation does not complement Xpert MTB/RIF in diagnosis of smear-negative pulmonary tuberculosis among TB-HIV co-infected adults in a resource-limited setting

    Article • BMC Infectious Diseases, January 2021, Springer Science + Business Media

    Willy SSENGOOBA

  55. Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial

    Article • Journal of Clinical Microbiology, August 2020, ASM Journals

    Willy SSENGOOBA

  56. A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region

    Article • Nature Communications, June 2020, Springer Science + Business Media

    Willy SSENGOOBA

  57. Typing and classification of non-tuberculous mycobacteria isolates

    Article • F1000Research, May 2020, Faculty of 1000, Ltd.

    Granger Sutton, Willy SSENGOOBA

  58. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda

    Article • PLOS One, May 2020, PLOS

    Willy SSENGOOBA, Dr Gerald Mboowa

  59. Typing and classification of non-tuberculous mycobacteria isolates

    Article • F1000Research, April 2020, Faculty of 1000, Ltd.

    Granger Sutton, Anthony Kiyimba, Willy SSENGOOBA

  60. Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance

    Article • Scientific Reports, August 2019, Springer Science + Business Media

    Willy SSENGOOBA

  61. Health seeking behavior among individuals presenting with chronic cough at referral hospitals in Uganda; Missed opportunity for early tuberculosis diagnosis

    Article • PLOS One, June 2019, PLOS

    Willy SSENGOOBA

  62. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study

    Article • PLOS One, May 2019, PLOS

    Irene Najjingo, Willy SSENGOOBA

  63. Determine TB –LAM Lateral Flow Assay, Does M. tuberculosis lineage influence its performance?

    Article • April 2019, Research Square

    Willy SSENGOOBA

  64. Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid

    Article • Journal of Clinical Microbiology, April 2019, ASM Journals

    Jerome Chin, Willy SSENGOOBA

  65. PO 8468 DETERMINE TB–LAM LATERAL FLOW ASSAY: DOES M. TUBERCULOSIS LINEAGE INFLUENCE ITS PERFORMANCE?

    Article • BMJ Global Health, April 2019, BMJ

    Willy SSENGOOBA

  66. Prevalence of Tuberculosis Risk Factors among Bacteriologically Negative and Bacteriologically Confirmed Tuberculosis Patients from Five Regional Referral Hospitals in Uganda

    Article • American Journal of Tropical Medicine and Hygiene, February 2019, American Society of Tropical Medicine and Hygiene

    Willy SSENGOOBA

  67. Xpert MTB/RIF Ultra: Optimal procedures for the detection of Mycobacterium tuberculosis in cerebrospinal fluid

    Article • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, February 2019, Elsevier

    Jerome Chin, Willy SSENGOOBA

  68. Agreement of Middle brook 7H10 with Lowenstein Jensen and accuracy of the Sensititre MYCOTB plate using either method as a reference standard for Mycobacterium tuberculosis first line drug susceptibility testing

    Article • PLOS One, June 2018, PLOS

    Willy SSENGOOBA

  69. Accuracy of different Xpert MTB/Rif implementation strategies in programmatic settings at the regional referral hospitals in Uganda: Evidence for country wide roll out

    Article • PLOS One, March 2018, PLOS

    Willy SSENGOOBA

  70. Performance of loop-mediated isothermal amplification assay in the diagnosis of pulmonary tuberculosis in a high prevalence TB/HIV rural setting in Uganda

    Article • BMC Infectious Diseases, February 2018, Springer Science + Business Media

    Willy SSENGOOBA

  71. Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda

    Article • The International Journal of Tuberculosis and Lung Disease, May 2017, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth, Willy SSENGOOBA

  72. Patient satisfaction with TB care clinical consultations in Kampala: a cross sectional study

    Article • African Health Sciences, March 2017, African Journals Online (AJOL)

    Willy SSENGOOBA

  73. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance

    Article • Nature Genetics, January 2017, Springer Science + Business Media

    Dr Valeriu Crudu, Willy SSENGOOBA

  74. Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda

    Article • BMC Infectious Diseases, November 2016, Springer Science + Business Media

    Willy SSENGOOBA

  75. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

    Article • Nature Genetics, October 2016, Springer Science + Business Media

    Jennifer Guthrie, Dr Valeriu Crudu, Willy SSENGOOBA

  76. Do Xpert MTB/RIF Cycle Threshold Values Provide Information about Patient Delays for Tuberculosis Diagnosis?

    Article • PLOS One, September 2016, PLOS

    Willy SSENGOOBA

  77. Whole genome sequencing reveals mycobacterial microevolution among concurrent isolates from sputum and blood in HIV infected TB patients

    Article • BMC Infectious Diseases, August 2016, Springer Science + Business Media

    Willy SSENGOOBA

  78. Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda

    Article • Infection Genetics and Evolution, June 2016, Elsevier

    Willy SSENGOOBA

  79. Prevalence and risk factors of latent Tuberculosis among adolescents in rural Eastern Uganda

    Article • African Health Sciences, September 2015, African Journals Online (AJOL)

    Willy SSENGOOBA

  80. Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology

    Article • PLOS One, July 2015, PLOS

    Willy SSENGOOBA

  81. High Genotypic Discordance of Concurrent Mycobacterium tuberculosis Isolates from Sputum and Blood of HIV-Infected Individuals

    Article • PLOS One, July 2015, PLOS

    Willy SSENGOOBA, Dr Gerald Mboowa

  82. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis

    Article • BMC Public Health, March 2015, Springer Science + Business Media

    Willy SSENGOOBA

  83. Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda

    Article • BMC Infectious Diseases, February 2015, Springer Science + Business Media

    Willy SSENGOOBA

  84. Improving the Sensitivity of the Xpert MTB/RIF Assay on Sputum Pellets by Decreasing the Amount of Added Sample Reagent: a Laboratory and Clinical Evaluation

    Article • Journal of Clinical Microbiology, February 2015, ASM Journals

    Willy SSENGOOBA, Dr Gerald Mboowa

  85. Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: implications for tuberculosis control

    Article • BMC Public Health, January 2015, Springer Science + Business Media

    Willy SSENGOOBA

  86. Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda

    Article • Health Research Policy and Systems, January 2015, Springer Science + Business Media

    Willy SSENGOOBA, Dr Gerald Mboowa

  87. Clinical Utility of a Novel Molecular Assay in Various Combination Strategies with Existing Methods for Diagnosis of HIV-Related Tuberculosis in Uganda

    Article • PLOS One, September 2014, PLOS

    Willy SSENGOOBA

  88. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert®MTB/RIF in Kampala, Uganda: a retrospective study

    Article • BMC Infectious Diseases, September 2014, Springer Science + Business Media

    Willy SSENGOOBA, Dr Gerald Mboowa

  89. Evaluation of Cepheid's Xpert MTB/RIF Test on Pleural Fluid in the Diagnosis of Pleural Tuberculosis in a High Prevalence HIV/TB Setting

    Article • PLOS One, July 2014, PLOS

    Willy SSENGOOBA

  90. A Comparison of Tools Used for Tuberculosis Diagnosis in Resource-Limited Settings: A Case Study at Mubende Referral Hospital, Uganda

    Article • PLOS One, June 2014, PLOS

    Willy SSENGOOBA

  91. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals

    Article • AIDS, June 2014, Wolters Kluwer Health

    Willy SSENGOOBA

  92. Prospective Cross-Sectional Evaluation of the Small Membrane Filtration Method for Diagnosis of Pulmonary Tuberculosis

    Article • Journal of Clinical Microbiology, May 2014, ASM Journals

    Willy SSENGOOBA

  93. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda

    Article • AIDS, November 2013, Wolters Kluwer Health

    Willy SSENGOOBA

  94. Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line Drugs

    Article • Antimicrobial Agents and Chemotherapy, October 2013, ASM Journals

    Willy SSENGOOBA, Dr Gerald Mboowa

  95. Burden of tuberculosis disease among adolescents in a rural cohort in Eastern Uganda

    Article • BMC Infectious Diseases, July 2013, Springer Science + Business Media

    Willy SSENGOOBA, Prof Robert Colebunders

  96. Molecular investigation of multiple strain infections in patients with tuberculosis in Mubende district, Uganda

    Article • Infection Genetics and Evolution, July 2013, Elsevier

    Willy SSENGOOBA

  97. Molecular Epidemiology, Drug Susceptibility and Economic Aspects of Tuberculosis in Mubende District, Uganda

    Article • PLOS One, May 2013, PLOS

    Willy SSENGOOBA

  98. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study

    Article • BMC Infectious Diseases, March 2013, Springer Science + Business Media

    Willy SSENGOOBA

  99. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda

    Article • BMC Infectious Diseases, February 2013, Springer Science + Business Media

    Willy SSENGOOBA, Dr Gerald Mboowa

  100. High incidence of pulmonary tuberculosis in children admitted with severe pneumonia in Uganda

    Article • BMC Pediatrics, January 2013, Springer Science + Business Media

    Willy SSENGOOBA

  101. Incremental Yield of Serial Sputum Cultures for Diagnosis of Tuberculosis among HIV Infected Smear Negative Pulmonary TB Suspects in Kampala, Uganda

    Article • PLOS One, May 2012, PLOS

    Willy SSENGOOBA

  102. An Early Morning Sputum Sample Is Necessary for the Diagnosis of Pulmonary Tuberculosis, Even with More Sensitive Techniques: A Prospective Cohort Study among Adolescent TB-Suspects in Uganda

    Article • Tuberculosis Research and Treatment, January 2012, Hindawi Publishing Corporation

    Willy SSENGOOBA, Dr Gerald Mboowa